Paradigmia
⌕Sign in ↗
Lessons

Other antitumour strategies

Created by: Alfredo Corell

Another way of getting the immune system to attack tumour cells is by enhancing their immunogenicity. For this, different active immunisation strategies can be followed, as happens with vaccines against pathogens.

Simple strategies can be used, such as identifying and purifying tumour antigens to use them as vaccines, in which the antigen is inoculated in small, controlled doses, so that the patient builds up antitumour cells and antibodies (for example, the BCR itself in certain lymphomas).

However, tumours generally have low immunogenicity. One possible strategy for increasing immunogenicity consists of activating the patient's dendritic cells “in vitro” with tumour antigens or even with crude tumour extracts, and reinjecting the cells into the patient. Dendritic cells are the most potent activators of T lymphocytes because they express class I and class II molecules and a large number of costimulatory molecules. In this way they could recognise the tumour antigens and activate T lymphocytes in vivo.

Another successful cell therapy makes use of conventional therapies. Often the tumour is removed and chemotherapy or radiotherapy is given. The excised tumour can be used to isolate the tumour-infiltrating lymphocytes, which are antitumour antibodies. These lymphocytes are stimulated with cytokines so that they multiply, and are then reinfused into the patient. It is a very good therapy as an adjuvant. They are tumour-specific cells.

Another possibility is gene therapy to stimulate the immune system, in which attempts are made to avoid the tumours' evasion mechanisms. For this, tumour cells are removed and CD80 or CD86 is injected into them; these are the membrane molecules that bind CD28 and provide the second stimulation signal for lymphocytes. In this way tumour cells will be recognised by T lymphocytes and will be activated much better → we make the tumour more immunogenic.

  • Other strategies: administration of cytokines in vivo, of microbial adjuvants such as LPS (used as non-specific activators of macrophages → they would then synthesise more TNFα and IFNα, and would phagocytose and present tumour Ag better to T lymphocytes).
Your study

Select a passage in the lesson. Your highlights are private.

0Back to course →
Keep exploring

Knowledge does not end here.

Paradigmia · YouTube ↗